factor v

Summary

Summary: Heat- and storage-labile plasma glycoprotein which accelerates the conversion of prothrombin to thrombin in blood coagulation. Factor V accomplishes this by forming a complex with factor Xa, phospholipid, and calcium (prothrombinase complex). Deficiency of factor V leads to Owren's disease.

Top Publications

  1. ncbi Malignancies, prothrombotic mutations, and the risk of venous thrombosis
    Jeanet W Blom
    Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands
    JAMA 293:715-22. 2005
  2. ncbi The mechanism of inactivation of human factor V and human factor Va by activated protein C
    M Kalafatis
    Department of Biochemistry, University of Vermont, College of Medicine, Burlington 05405 0068
    J Biol Chem 269:31869-80. 1994
  3. ncbi Blood group AB and factor V Leiden as risk factors for pre-eclampsia: a population-based nested case-control study
    Leena M Hiltunen
    Department of Hemostasis, Finnish Red Cross Blood Service, Helsinki, Finland
    Thromb Res 124:167-73. 2009
  4. ncbi Varied prevalence of factor V G1691A (Leiden) and prothrombin G20210A single nucleotide polymorphisms among Arabs
    Wassim Y Almawi
    Al Jawhara Center for Molecular Medicine, Genetics and Inherited Diseases, College of Medicine and Medical Sciences, Arabian Gulf University, Manama, Bahrain
    J Thromb Thrombolysis 20:163-8. 2005
  5. ncbi Combined Factor V and Factor VIII Deficiency
    Marta Spreafico
    A Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Medicine and Medical Specialties, IRCCS Maggiore Hospital, Mangiagalli and Regina Elena Foundation, University of Milan, 20122 Milan, Italy
    Semin Thromb Hemost 35:390-9. 2009
  6. ncbi Factor V Leiden and prothrombin gene G20210A mutations are uncommon in portal vein thrombosis in India
    Sanjay Sharma
    Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow 226 014, India
    Indian J Gastroenterol 25:236-9. 2006
  7. ncbi Prevalence of factor V Leiden, prothrombin and methylene tetrahydrofolate reductase mutations in women with adverse pregnancy outcomes in Lebanon
    Laila F Zahed
    Department of Pathology and Laboratory Medicine, American University of Beirut Medical Center, Lebanon
    Am J Obstet Gynecol 195:1114-8. 2006
  8. ncbi Prevalence and association of the factor V Leiden and prothrombin G20210A in healthy subjects and patients with venous thromboembolism
    D Coen
    Clinical Institute of Laboratory Diagnostics, Zagreb University Hospital Center, Zagreb, Croatia
    Croat Med J 42:488-92. 2001
  9. ncbi Factor V Leiden G1691A and prothrombin G20210A mutations are common in Tunisia
    C Frere
    J Thromb Haemost 1:2451-2. 2003
  10. ncbi Prevalence of antiphospholipid antibodies, factor V G1691A (Leiden) and prothrombin G20210A mutations in early and late recurrent pregnancy loss
    Nabil Mtiraoui
    Research Unit of Haematological and Autoimmune Diseases, Faculty of Pharmacy, Monastir, Center University, Tunisia
    Eur J Obstet Gynecol Reprod Biol 119:164-70. 2005

Research Grants

  1. MOLECULAR BIOLOGY OF HUMAN COAGULATION FACTOR V
    Thomas Ortel; Fiscal Year: 2010
  2. MOLECULAR BIOLOGY OF HUMAN COAGULATION FACTOR V
    WILLIAM KANE; Fiscal Year: 2009
  3. NICHD Maternal Fetal Medicine Units Network
    Brian Mercer; Fiscal Year: 2007
  4. FACTOR VA INTERACTIONS REGULATING PROTHROMBIN ACTIVATION
    Paul Bock; Fiscal Year: 2007
  5. FACTOR VA INTERACTIONS REGULATING PROTHROMBIN ACTIVATION
    Paul E Bock; Fiscal Year: 2010
  6. MOLECULAR BIOLOGY OF HUMAN COAGULATION FACTOR V
    WILLIAM KANE; Fiscal Year: 2004
  7. MOLECULAR BIOLOGY OF HUMAN COAGULATION FACTOR V
    WILLIAM KANE; Fiscal Year: 2007
  8. MOLECULAR BIOLOGY OF HUMAN COAGULATION FACTOR V
    WILLIAM KANE; Fiscal Year: 1993
  9. Surrogate markers for Severe Pulmonary Embolism
    JEFFREY KLINE; Fiscal Year: 2005
  10. Epidemiologic Study of Placental Abruption
    Cande Ananth; Fiscal Year: 2006

Detail Information

Publications231 found, 100 shown here

  1. ncbi Malignancies, prothrombotic mutations, and the risk of venous thrombosis
    Jeanet W Blom
    Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands
    JAMA 293:715-22. 2005
    ..all patients and controls were interviewed, a blood sample was taken, and DNA was isolated to ascertain the factor V Leiden and prothrombin 20210A mutations. MAIN OUTCOME MEASURE: Risk of venous thrombosis...
  2. ncbi The mechanism of inactivation of human factor V and human factor Va by activated protein C
    M Kalafatis
    Department of Biochemistry, University of Vermont, College of Medicine, Burlington 05405 0068
    J Biol Chem 269:31869-80. 1994
    The cleavage of human factor V and human factor Va by human activated protein C (APC) was analyzed in the absence and presence of phospholipid vesicles containing 75% phosphatidylcholine (PC) and 25% phosphatidylserine (PS)...
  3. ncbi Blood group AB and factor V Leiden as risk factors for pre-eclampsia: a population-based nested case-control study
    Leena M Hiltunen
    Department of Hemostasis, Finnish Red Cross Blood Service, Helsinki, Finland
    Thromb Res 124:167-73. 2009
    ..ABO blood group has been associated with thrombotic disorders and pre-eclampsia. We assessed ABO blood group, seven thrombophilia associated polymorphisms, and anti-beta2-glycoprotein I antibodies as risk factors for pre-eclampsia...
  4. ncbi Varied prevalence of factor V G1691A (Leiden) and prothrombin G20210A single nucleotide polymorphisms among Arabs
    Wassim Y Almawi
    Al Jawhara Center for Molecular Medicine, Genetics and Inherited Diseases, College of Medicine and Medical Sciences, Arabian Gulf University, Manama, Bahrain
    J Thromb Thrombolysis 20:163-8. 2005
    b>Factor V G1691A (FV-Leiden) and prothrombin (PRT) G20210A single nucleotide polymorphisms (SNPs) are major inherited risk factors of venous thromboembolism...
  5. ncbi Combined Factor V and Factor VIII Deficiency
    Marta Spreafico
    A Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Medicine and Medical Specialties, IRCCS Maggiore Hospital, Mangiagalli and Regina Elena Foundation, University of Milan, 20122 Milan, Italy
    Semin Thromb Hemost 35:390-9. 2009
    Combined deficiency of factor V (FV) and factor VIII (FVIII) (F5F8D, or FV+FVIII) is a autosomal recessive bleeding disorder caused by mutations in genes encoding two components of the endoplasmic reticulum (ER)-Golgi intermediate ..
  6. ncbi Factor V Leiden and prothrombin gene G20210A mutations are uncommon in portal vein thrombosis in India
    Sanjay Sharma
    Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow 226 014, India
    Indian J Gastroenterol 25:236-9. 2006
    ..The cause of thrombosis in these patients remains unclear. We studied the frequency of mutations in genes for coagulation factors V and II (prothrombin) in 61 Indian patients with PVT and 49 healthy control subjects...
  7. ncbi Prevalence of factor V Leiden, prothrombin and methylene tetrahydrofolate reductase mutations in women with adverse pregnancy outcomes in Lebanon
    Laila F Zahed
    Department of Pathology and Laboratory Medicine, American University of Beirut Medical Center, Lebanon
    Am J Obstet Gynecol 195:1114-8. 2006
    The purpose of this study was to determine the prevalence of factor V Leiden, prothrombin, and methylene tetrahydrofolate reductase gene mutations in women with adverse pregnancy outcome compared with women who had uneventful pregnancies.
  8. ncbi Prevalence and association of the factor V Leiden and prothrombin G20210A in healthy subjects and patients with venous thromboembolism
    D Coen
    Clinical Institute of Laboratory Diagnostics, Zagreb University Hospital Center, Zagreb, Croatia
    Croat Med J 42:488-92. 2001
    To determine the prevalences of factor V Leiden and the G20210A mutation in the prothrombin gene (PT20210A) and the frequency of their association in healthy subjects and in patients with venous thromboembolism (VTE).
  9. ncbi Factor V Leiden G1691A and prothrombin G20210A mutations are common in Tunisia
    C Frere
    J Thromb Haemost 1:2451-2. 2003
  10. ncbi Prevalence of antiphospholipid antibodies, factor V G1691A (Leiden) and prothrombin G20210A mutations in early and late recurrent pregnancy loss
    Nabil Mtiraoui
    Research Unit of Haematological and Autoimmune Diseases, Faculty of Pharmacy, Monastir, Center University, Tunisia
    Eur J Obstet Gynecol Reprod Biol 119:164-70. 2005
    ..We assessed the prevalence of inherited (FV-Leiden and PRT G20210A), and acquired (anti-PL antibodies) risk factors among habitual aborters in Tunisia...
  11. ncbi Prevalence of factor V leiden, factor V cambridge, factor II G20210A and methylenetetrahydrofolate reductase C677T mutations in healthy and thrombophilic Serbian populations
    V Djordjevic
    Institute of Molecular Genetics and Genetic Engineering, Belgrade, Serbia and Montenegro
    Acta Haematol 112:227-9. 2004
  12. ncbi Prevalence of factor V Leiden, prothrombin G20210A, and MTHFR C677T mutations in 200 healthy Jordanians
    Suhair S Eid
    Molecular Laboratory, King Hussein Medical Centre, Jordan
    Clin Lab Sci 17:200-2. 2004
    ..In order to estimate the frequency of the factor V Leiden, prothrombin G20210A, and MTHFR C677T mutations in the Jordanian population, we screened 200 healthy ..
  13. ncbi Prevalence of factor V Leiden mutation and other hereditary thrombophilic factors in Egyptian children with portal vein thrombosis: results of a single-center case-control study
    Hanaa El-Karaksy
    Department of Pediatrics, Faculty of Medicine, Cairo University, Cairo, Egypt
    Ann Hematol 83:712-5. 2004
    ..Our aim was to assess the prevalence of factor V Leiden mutation and other thrombophilic factors as risk factors in the development of PVT in the pediatric age ..
  14. ncbi Prevalence of two thrombophilia predisposing mutations: factor V G1691A (R506Q; Leiden) and prothrombin G20210A, among healthy Lebanese
    Hala Tamim
    Thromb Haemost 88:691-2. 2002
  15. ncbi Allelic frequency of the factor V Leiden mutation and of the pro-thrombin gene 20210A mutation in healthy Tunisian population
    Lobna Bouaziz
    Thromb Haemost 91:824-5. 2004
  16. ncbi Absence of factor V Leiden mutation and low prothrombin G 20210 A mutation prevalence in a healthy Moroccan population
    Florence Mathonnet
    Thromb Haemost 88:1073-4. 2002
  17. ncbi Prevalence of factor V Leiden in patients with myocardial infarction and normal coronary angiography
    J Mansourati
    Cardiology Department of Brest, North Hospital of Saint Etienne, France
    Thromb Haemost 83:822-5. 2000
    b>Factor V Leiden is associated with an increased risk of venous thrombosis and myocardial infarction in young women, but not in men in this latter case...
  18. ncbi Prevalence of factor V Leiden and prothrombin G20210A mutation in a large French population selected for nonthrombotic history: geographical and age distribution
    Elisabeth Mazoyer
    Hématologie biologique, Hopital Lariboisiere, Paris, France
    Blood Coagul Fibrinolysis 20:503-10. 2009
    ..These polymorphisms confer a very mild hypercoagulable state as shown by the limited increased in basal D-dimers in mutated FV-G1691A populations and only a trend that does not reach statistical significance for FII-G20210A population...
  19. ncbi High incidence of factor V Leiden and prothrombin G20210A in healthy southern Italians
    Gianluca Sottilotta
    Centro Emofilia, Servizio Emostasi e Trombosi, Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy
    Clin Appl Thromb Hemost 15:356-9. 2009
    b>Factor V Leiden (FVL) and G20210 prothrombin (FII G20210A) mutations are risk factors for thromboembolism...
  20. ncbi Deep venous thrombosis and thrombophilic mutations in western Iran: association with factor V Leiden
    Zohreh Rahimi
    Medical Biology Research Center, Kermanshah University of Medical Sciences, Iran
    Blood Coagul Fibrinolysis 21:385-8. 2010
    The aim of present study was to investigate the prevalence of factor V Leiden (FVL) c.1691G>A, prothrombin g.20210G>A and methylenetetrahydrofolate reductase (MTHFR) c...
  21. ncbi Prevalence of angiotensin-converting enzyme, methylenetetrahydrofolate reductase, Factor V Leiden, prothrombin and apolipoprotein E gene polymorphisms in Morocco
    Thierry Paluku They-They
    Laboratoire de Génétique Médicale et Pathologie Moléculaire LGPM, Faculté de Médecine et de Pharmacie Casablanca, 19 rue Tarik Ibn Ziad, Casablanca, Morocco
    Ann Hum Biol 37:767-77. 2010
    ..These genetic factors are involved in several pathways affecting blood pressure regulation, blood coagulation, homocysteine and lipid metabolisms...
  22. ncbi Distinct association of factor V-Leiden and prothrombin G20210A mutations with deep venous thrombosis in Tunisia and Lebanon
    Lobna Bouaziz-Borgi
    Faculty of Pharmacy, University of Monastir, Tunisia
    Am J Hematol 81:641-3. 2006
    b>Factor V G1691A (FV-Leiden) and prothrombin (PRT) G20210A single nucleotide polymorphisms (SNPs) were associated with venous thrombosis among Caucasians...
  23. ncbi Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review
    Jodi B Segal
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    JAMA 301:2472-85. 2009
    ..Testing for genetic risks for venous thromboembolism (VTE) is common, but the safety and utility of such testing need review...
  24. ncbi Prothrombotic mutations as risk factors for cryptogenic ischemic cerebrovascular events in young subjects with patent foramen ovale
    Nicoletta Botto
    CNR Institute of Clinical Physiology, G Pasquinucci Hospital, Massa, Italy
    Stroke 38:2070-3. 2007
    ..We evaluated the prevalence of the 2 most common genetic risk factors for thromboembolism, factor V Leiden (G1691A) and prothrombin G20210A, in young PFO patients who were referred for percutaneous transcatheter ..
  25. ncbi Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening
    P M Ridker
    Division of Preventive Medicine, Brigham and Women s Hospital, Boston, MA 02215 1204, USA
    JAMA 277:1305-7. 1997
    To estimate ethnic-specific prevalence rates of factor V Leiden, an inherited defect of hemostasis associated with risk of venous thrombosis.
  26. ncbi Factor V Leiden and prothrombin gene mutation may predispose to paradoxical embolism in subjects with patent foramen ovale
    Vesa Karttunen
    Department of Neurology, Oulu University Central Hospital, Box 25, FIN 90029 Oulu, Finland
    Blood Coagul Fibrinolysis 14:261-8. 2003
    ..We assessed the occurrence of several prothrombotic states (factor V Leiden, prothrombin G20210A, deficiencies in protein S, protein C and antithrombin, lupus anticoagulant, ..
  27. ncbi Renin-angiotensin system and haemostasis gene polymorphisms and outcome after coronary artery bypass graft surgery
    Henry Volzke
    Department of Epidemiology and Social Medicine, Ernst Moritz Arndt University, Walther Rathenau Str 48, D 17487 Greifswald, Germany
    Int J Cardiol 98:133-9. 2005
    ..system (angiotensinogen 235 M/T, angiotensin II type 1 receptor 1166 A/C) or the clotting system (glycoprotein IIIa PlA1/PlA2 and factor V Leiden 1691 G/A) are associated with the outcome after coronary artery bypass grafting.
  28. ncbi Homozygous Factor V Leiden mutation in sickle cell anaemia
    U Kordes
    Br J Haematol 116:236. 2002
  29. ncbi Prevalence of factor V leiden mutation in patients with thrombosis in Tunisia
    A Ajem
    Immunogenetic Unit, Faculty of Medicine of Sousse, Sousse, Tunisia
    East Mediterr Health J 15:1483-8. 2009
    This study determined the prevalence of inherited factor V Leiden mutation in a group of 128 thrombosis patients (102 with venous thrombosis and 26 with arterial thrombosis) attending a hospital in Sousse, Tunisia, and a control group of ..
  30. ncbi Association of factor V Leiden and prothrombin gene mutation with Behçet's disease
    U Tursen
    Department of Dermatology, Faculty of Medicine, Mersin University, Turkey
    Arch Dermatol Res 293:537-9. 2001
  31. ncbi Prevalence of factor V Leiden and prothrombin G20210A gene mutation
    Ahmet Irdem
    Department of Pediatrics, Faculty of Medicine, Dicle University, Diyarbakir, Turkey
    Saudi Med J 26:580-3. 2005
    To determine the prevalence of factor V Leiden (FVL) and prothrombin gene (PG) 20210A mutations in patients who attended the outpatient clinic and do not have a family history of thrombosis.
  32. ncbi The impact of heterozygosity for the factor V Leiden and factor II G20210A mutations on the risk of thrombosis in Greek patients
    A Hatzaki
    Molecular Biology Department Research Center HYGEIA Antonis Papayiannis, Athens, Greece
    Int Angiol 22:79-82. 2003
    ..The goal of this study was to examine the efficiency of the selection criteria for performing a genetic test for the factor V G1691A (Leiden) and factor II G20210A mutations.
  33. ncbi Prevalence of factor V Leiden, prothrombin G20210A, and MTHFR G677A among 594 thrombotic Jordanian patients
    Suhair S Eid
    King Hussein Medical Center, Princess Iman Research Center for Laboratory Sciences, Amman, Jordan
    Blood Coagul Fibrinolysis 16:417-21. 2005
    ..In order to estimate the frequency of factor V Leiden, prothrombin G20210A, and MTHFR C677T mutations in Jordanian thrombotic patients, we studied 594 patients ..
  34. ncbi An Arab selective gradient in the distribution of factor V G1691A (Leiden), prothrombin G20210A, and methylenetetrahydrofolate reductase (MTHFR) C677T
    G Ameen
    J Thromb Haemost 3:2126-7. 2005
  35. ncbi Influence of the 4600A/G and 4678G/C polymorphisms in the endothelial protein C receptor (EPCR) gene on the risk of venous thromboembolism in carriers of factor V Leiden
    Pilar Medina
    Research Center, La Fe University Hospital, Valencia, Spain
    Thromb Haemost 94:389-94. 2005
    ..The objective of this study was to assess whether these polymorphisms modify the risk of VTE in carriers of factor V (FV) Leiden...
  36. ncbi Decision analysis model of prolonged oral anticoagulant treatment in factor V Leiden carriers with first episode of deep vein thrombosis
    F P Sarasin
    Medical Clinics, Hospital Cantonal, University of Geneva Medical School, Switzerland
    BMJ 316:95-9. 1998
    ..treatment extended beyond 3 months after a first episode of deep vein thrombosis in patients who carry factor V Leiden mutation...
  37. ncbi Arterial thrombosis associated with heterozygous factor V Leiden disorder, hyperhomocysteinemia, and peripheral arterial disease: importance of synergistic factors
    Cameron Page
    Department of Surgery, VA Connecticut Healthcare System, Yale University School of Medicine, New Haven, CT 06519, USA
    J Vasc Surg 42:1014-8. 2005
    A 47-year-old man with heterozygous factor V Leiden disorder and intermittent hyperhomocysteinemia developed spontaneous acute popliteal artery thrombosis. Homocysteine levels were above normal limits at presentation...
  38. ncbi Frequent occurrence of anticardiolipin antibodies, Factor V Leiden mutation, and perturbed endothelial function in chronic myeloproliferative disorders
    Morten Krogh Jensen
    Department of Haematology, Rigshospitalet, University Hospital of Copenhagen, Denmark
    Am J Hematol 69:185-91. 2002
    ..021; patients vs. controls). Seven patients were heterozygous for the Factor V Leiden, one patient was heterozygous for the prothrombin G20210A mutation, and one patient was homozygous for the ..
  39. ncbi Factor V 1691 G-A mutation in children with intracardiac thrombosis: a prospective study
    S Atalay
    Department of Pediatric Cardiology, Ankara University, Turkey
    Acta Paediatr 91:168-71. 2002
    ..to determine the association between intracardiac thrombosis and hereditary causes of thrombophilia, including factor V 1691 G-A (factor V Leiden, FVL) and prothrombin 20210 G-A mutations...
  40. ncbi Factor V Leiden and prothrombin gene 20210A variant in neonatal thromboembolism and in healthy neonates and adults: a study in a single center
    Begum Atasay
    Division of Neonatology, Department of Pediatrics, Ankara University School of Medicine, Ankara, Turkey
    Pediatr Hematol Oncol 20:627-34. 2003
    ..Investigations included screening for factor V 1691A and prothrombin 20210A. Seven of 9 neonates had one or more risk factors at the time of thromboembolism...
  41. ncbi Prevalence of resistance against activated protein C resulting from factor V Leiden is significantly increased in myocardial infarction: investigation of 507 patients with myocardial infarction
    Katharina Middendorf
    Medical Clinic I, Klinikum Grosshadern, Ludwig Maximilian University, Munich, Germany
    Am Heart J 147:897-904. 2004
    A point mutation in the gene encoding coagulation factor V is a cause of resistance against activated protein C. The presence of factor V Leiden is linked to 50% of congenital defects causing venous thrombosis...
  42. ncbi High frequency of factor V Leiden and prothrombin G20210A mutations in Greek hemophiliacs
    Z J Foka
    J Thromb Haemost 1:1116-7. 2003
  43. ncbi Race differences in the prevalence of the factor V Leiden mutation in Kuwaiti nationals
    Ali A Dashti
    Department of Medical Laboratory Sciences, Faculty of Allied Health Sciences, Kuwait University, P O Box 31470, 90805, Sulaibekhat, Kuwait
    Mol Biol Rep 38:3623-8. 2011
    b>Factor V Leiden mutation (FVL; G1691A) is an established risk factor for venous thromboembolic disorders. FVL was reported with high prevalence in Caucasians (1-15%) but was absent in non-Caucasians like Africans and Asians...
  44. ncbi Association between factor V Leiden mutation and poor pregnancy outcomes among Palestinian women
    Ayman S Hussein
    Faculty of Medicine, An Najah National University, Nablus, Palestine
    Thromb Res 126:e78-82. 2010
    ..Among the inherited risk factors is Factor V Leiden mutation, an autosomal dominant trait with reduced penetrance...
  45. ncbi Factor V Leiden thrombophilia
    Jody Lynn Kujovich
    Northwest Cancer Specialists, Portland, OR 97227, USA
    Genet Med 13:1-16. 2011
    b>Factor V Leiden is a genetic disorder characterized by a poor anticoagulant response to activated Protein C and an increased risk for venous thromboembolism...
  46. ncbi Factor V Leiden and prothrombin G20210A mutations in pregnancies with adverse outcome
    T Agorastos
    First University Department of Obstetrics and Gynecology, Medical School, Aristotle University of Thessaloniki, Greece
    J Matern Fetal Neonatal Med 12:267-73. 2002
    ..The aim of this study was to investigate the relationship between specific obstetric adverse outcomes and factor V Leiden and prothrombin G20210A mutations.
  47. ncbi Purpura fulminans in a child with combined heterozygous prothrombin G20210A and factor V Leiden mutations
    N Ozbek
    Department of Pediatrics, Baskent University Faculty of Medicine, 6 Cadde No 72 3, 06490 Bahcelievler, Ankara, Turkey
    Ann Hematol 82:118-20. 2003
    ..This article highlights a case of a child with severe arterial thrombosis who was heterozygous for the factor V Leiden (FVL) and prothrombin G20210A mutations...
  48. ncbi Extensive arterial thrombosis in a patient with factor V Leiden mutation
    Mohammad Hossein Mandegar
    Day General Hospital, Tavanir St, Vali Asr Ave, Tehran, Iran
    Interact Cardiovasc Thorac Surg 11:127-9. 2010
    ..Here, we report the case of a young male patient with factor V Leiden mutation who developed ascending aorta and aortic arch thrombosis and subsequent emboli.
  49. ncbi Prevalence of factor V Leiden and G6PD 1311 silent mutations in Dalmatian population
    Vedrana Cikes
    Laboratory for Molecular Biology, University of Split, School of Medicine, Split, Croatia
    Arch Med Res 35:546-8. 2004
    BACKGROUND: Factor V Leiden has been described as a common genetic risk factor for venous thromboembolism. The geographic distribution of this abnormality varies greatly, being high in Europe and almost absent in Asia and Africa...
  50. ncbi Thrombophilia in cardiac surgery-patients with symptomatic factor V Leiden
    Parwis Massoudy
    Department for Thoracic and Cardiovascular Surgery, West German Heart Center Essen, Hufelandstrasse 55, Essen, Germany
    J Card Surg 24:379-82. 2009
    Thrombophilia may cause severe complications in cardiac surgical patients. We analyzed our experience with symptomatic factor V Leiden patients.
  51. ncbi Thrombosis in children with cardiac pathology: frequency of factor V Leiden and prothrombin G20210A mutations
    A Gurgey
    Department of Pediatrics, Pediatric Hematology Unit, Hacettepe University, Faculty of Medicine, Ihsan Dogramac? Children's Hospital, 06100, Ankara, Turkey
    Pediatr Cardiol 24:244-8. 2003
    ..Two common mutations, namely factor V Leiden and prothrombin G20210A mutations, were found in 6 patients (22%)...
  52. ncbi Thrombophilic mutations among Southern Iranian patients with sickle cell disease: high prevalence of factor V Leiden
    Zohreh Rahimi
    Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
    J Thromb Thrombolysis 25:288-92. 2008
    ..In a case-control study, the prevalence of factor V Leiden and prothrombin G20210A mutations were investigated among SCD patients from Southern Iran.
  53. ncbi Genotyping of factor V G1691A (Leiden) without the use of PCR by invasive cleavage of oligonucleotide probes
    M J Hessner
    The Diagnostic Laboratories of The Blood Center of Southeastern Wisconsin, Milwaukee, WI 53201 2178, USA
    Clin Chem 46:1051-6. 2000
    The factor V G1691A Leiden (FVL) mutation is the most common known hereditary risk factor for venous thrombosis.
  54. ncbi Lower contribution of factor V Leiden or G202104 mutations to ischemic stroke in patients with clinical risk factors: pair-matched case-control study
    Davor Eterovic
    Department of Physiology and Biophysics, Medical School at Split, Croatia
    Clin Appl Thromb Hemost 13:188-93. 2007
    It was suggested that factor V Leiden and prothrombin G20210A mutations increase the risk of ischemic stroke only in combination with clinical risk factors of arterial ischemic disease...
  55. ncbi The risk of venous thromboembolism in family members with mutations in the genes of factor V or prothrombin or both
    I Martinelli
    Angelo Bianchi Bonomi Haemophilia and Thrombosis Centre, IRCCS Maggiore Hospital, University of Milan, Italy
    Br J Haematol 111:1223-9. 2000
    b>Factor V Leiden and the G20210A mutation in the prothrombin gene are the most frequent abnormalities associated with venous thromboembolism. It is unknown whether the risks due to the presence of either mutation are of the same magnitude...
  56. ncbi Factor V Leiden and prothrombin gene G 20210 A variant in children with ischemic stroke
    W Zenz
    Department of Pediatrics, University of Graz, Austria
    Thromb Haemost 80:763-6. 1998
    To investigate if the factor V Leiden mutation (F-V-LM) and/or the prothrombin gene G 20210 A variant (P-G20210A-V) are risk factors for acute stroke in Austrian children.
  57. ncbi The O blood group protects against venous thromboembolism in individuals with the factor V Leiden but not the prothrombin (factor II G20210A) mutation
    A J González Ordóñez
    Hematology Department, Hospital S Agustín, Aviles, Spain
    Blood Coagul Fibrinolysis 10:303-7. 1999
    We investigated the influence of the ABO blood group in the observed prevalences of the recently described factor V R506Q and factor II G20210A mutations in a thrombotic population...
  58. ncbi Analysis of the factor V Leiden mutation using the READIT Assay
    R B Rhodes
    University of Minnesota, Minneapolis, MN, USA
    Mol Diagn 6:55-61. 2001
    ..We show the application of a novel SNP scoring tool for analysis of the factor V Leiden mutation. METHODS AND RESULTS: We have developed a novel method for analyzing SNPs...
  59. ncbi Population genetics of factor V Leiden in Europe
    G Lucotte
    International Institute of Anthropology, 1 place d Iéna, Paris 16ème, France
    Blood Cells Mol Dis 27:362-7. 2001
    ..originating from 26 geographically defined populations in Europe and neighboring countries for the presence of factor V Leiden, an important genetic risk factor in venous thromboembolism...
  60. ncbi Aortic arch thrombosis in a neonate with heterozygous carrier status of factor V Leiden mutation
    Tuuli Metsvaht
    Clinic of Anesthesiology and Intensive Care, Tartu University Clinics, Tartu, Estonia
    Congenit Heart Dis 1:40-5. 2006
    ..Heterozygous carrier status of the factor V Leiden mutation was diagnosed as a single prothrombotic risk factor...
  61. ncbi Factor V Leiden mutation in venous thrombosis in southeast Turkey
    Sevgi Kalkanli
    Department of Medical Genetic Biology, University of Dicle, Diyarbakir, Turkey
    Angiology 57:193-6. 2006
    ..b>Factor V Leiden mutation (G1691A) (FVL) is the most common risk factor in venous thrombosis...
  62. ncbi Association of factor V gene polymorphisms (Leiden; Cambridge; Hong Kong and HR2 haplotype) with recurrent idiopathic pregnancy loss in Tunisia. A case-control study
    Walid Zammiti
    Research Unit of Haematological and Autoimmune Diseases, Faculty of Pharmacy, Monastir, Center University, Tunisia
    Thromb Haemost 95:612-7. 2006
    ..We performed a case-control study on the association between thrombosis-related polymorphisms in the factor V (FV) gene (Leiden, Cambridge, Hong Kong; HR2 haplotype) and idiopathic recurrent pregnancy loss (RPL) in Tunisian ..
  63. ncbi The prevalence of factor V Leiden (G1691A), prothrombin G20210A and methylenetetrahydrofolate reductase C677T mutations in Jordanian patients with beta-thalassemia major
    Suleimman A Al-Sweedan
    Department of Pediatrics, Jordan University of Science and Technology, Irbid, Jordan
    Blood Coagul Fibrinolysis 20:675-8. 2009
    One hundred beta-thalassemia major (beta-TM) patients and 100 individuals as control were included. Factor V Leiden and prothrombin G20210A and methylenetetrahydrofolate reductase (MTHFR) gene mutations were genotyped by PCR and allele-..
  64. ncbi Impact of thrombophilic genetic factors on pulmonary embolism: early onset and recurrent incidences
    Petar Ivanov
    Department of Biochemistry, University of Medicine, 1, St Kliment Ohridski Str, Pleven, 5800, Bulgaria
    Lung 186:27-36. 2008
    ..b>Factor V Leiden (FVL), prothrombin gene mutation G20210A (FII G20210), genetic variant C677T of the ..
  65. ncbi Hyperhomocysteinemia and other newly recognized inherited coagulation disorders (factor V Leiden and prothrombin gene mutation) in patients with idiopathic cerebral vein thrombosis
    Paolo Ventura
    Department of Internal Medicine, University of Modena and Reggio Emilia, Italy
    Cerebrovasc Dis 17:153-9. 2004
    ..New, inherited - factor V Leiden (FVL) and prothrombin gene mutation (PTHRA20210) - and inherited/acquired - hyperhomocysteinemia (HHcy) - ..
  66. ncbi The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus
    Jan Leendert P Brouwer
    Division of Haemostasis, Thrombosis and Rheology, Department of Hematology, University Hospital Groningen The Netherlands
    Blood 104:143-8. 2004
    ..We assessed the contribution of deficiencies of antithrombin, protein C, total protein S, factor V Leiden, the prothrombin G20210A mutation and APC resistance, either alone or in various combinations with LA and/..
  67. ncbi Are patients with thrombophilia and previous venous thromboembolism at higher risk to arterial thrombosis?
    Birgit Linnemann
    Division of Vascular Medicine, Department of Internal Medicine, Johann Wolfgang Goethe University Hospital, Theodor Stern Kai 7 D 60590 Frankfurt Main, Germany
    Thromb Res 121:743-50. 2008
    ..Whether thrombophilic disorders, which are established risk factors for venous thromboembolism (VTE), also increase the risk of arterial thrombosis is still unknown...
  68. ncbi Inherited thrombophilic abnormalities and risk of portal vein thrombosis. a meta-analysis
    Francesco Dentali
    Department of Clinical Medicine, University of Insubria, Viale Borri 57, Varese, 21100, Italy
    Thromb Haemost 99:675-82. 2008
    ..It was the purpose of this study to assess the risk of PVT associated with factor V Leiden (FVL) and G20210A prothrombin mutation (PTM)...
  69. ncbi The epidemiology of venous thromboembolism in Caucasians and African-Americans: the GATE Study
    N F Dowling
    Haematologic Diseases Branch, Division of AIDS, STD, and TB Laboratory Research, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA
    J Thromb Haemost 1:80-7. 2003
    ..Race-adjusted odds ratios for the associations of factor V Leiden and prothrombin G20210A mutations were 3.1 (1.5, 6.7) and 1.9 (0.8, 4.4), respectively...
  70. ncbi Effect of hemostatic risk factors on the individual probability of thrombosis during pregnancy and the puerperium
    Andrea Gerhardt
    Department of Hemostasis and Tansfusion Medicine, Heinrich Heine University Medical Center, Dusseldorf, Germany
    Thromb Haemost 90:77-85. 2003
    ..overall risk of 1 in 1500 pregnancies, the probability of pregnancy-related thrombosis in carriers of homozygous factor V Leiden was 1 in 80 (odds ratio 20.6, p=0...
  71. ncbi [Genetic determinants of hereditary thrombophilia in pathogenesis of venous thrombosis]
    S I Kapustin
    Ter Arkh 75:78-80. 2003
    ..MATERIAL AND METHODS: Mutations of the genes of factor V (FV Leiden), prothrombin (G20210-A) and polymorphism C677-T in the gene of methylentetrahydrofolate reductase (..
  72. ncbi Clinical evaluation of a functional prothrombin time-based assay for identification of factor V Leiden carriers in a group of Italian patients with venous thrombosis
    Gianluca Gessoni
    Clinical Pathology Laboratory, Ospedale Civile, Chioggia, Venice, Italy
    Blood Coagul Fibrinolysis 18:603-10. 2007
    The efficiency of a new prothrombin-based activated protein C (APC) resistance test to detect factor V Leiden (FVL) was clinically evaluated in 150 Italian patients with deep venous thrombosis...
  73. ncbi Early postoperative obstructive prosthetic mitral valve thrombosis in a patient double heterozygous for factor V Leiden and prothrombin G20210A mutation
    Stefano De Paulis
    Dipartimento di Medicina Cardiovascolare, Policlinico A. Gemelli, Catholic University, Largo Gemelli 8, Rome, Italy
    Thromb Haemost 99:441-2. 2008
  74. ncbi Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study
    E R Pomp
    Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands
    J Thromb Haemost 6:632-7. 2008
    ..Objective: In the MEGA study, we evaluated pregnancy and the postpartum period as risk factors for venous thrombosis in 285 patients and 857 control subjects...
  75. ncbi Thrombosis in inherited factor VII deficiency
    G Mariani
    Cattedra e Divisione di Ematologia, Universita di Palermo, Palermo University Hospital, Via del Vespro 127, 90127 Palermo, Italy
    J Thromb Haemost 1:2153-8. 2003
    ..In particular, severe FVII deficiency did not seem to offer protection from strong thrombosis risk factors such as surgery and replacement therapy...
  76. ncbi Molecular analysis of factor V Leiden, factor V Hong Kong, factor II G20210A, methylenetetrahydrofolate reductase C677T, and A1298C mutations related to Turkish thrombosis patients
    Bilgen Dolek
    Department of Molecular Biology and Genetics, Istanbul University, Istanbul, Turkey
    Clin Appl Thromb Hemost 13:435-8. 2007
    ..The roles of factor V Hong Kong (FV Hong Kong), factor V Leiden (FV Leiden), factor II G20210A (FII G20210A), methylenetetrahydrofolate ..
  77. ncbi Relationship between thrombophilic disorders and type of severe early-onset hypertensive disorder of pregnancy
    Wessel Ganzevoort
    Department of Obstetrics and Gynaecology, Academic Medical Centre, Amsterdam, The Netherlands
    Hypertens Pregnancy 26:433-45. 2007
    ....
  78. ncbi Deep vein thrombosis followed by internal jugular vein thrombosis as a complication of in vitro fertilization in a woman heterozygous for the prothrombin 3' UTR and factor V Leiden mutations
    B M C McGowan
    Haemophilia and Haemostasis Unit, Department of Haematology, Royal Free and University College Medical School, London, England
    Am J Hematol 73:276-8. 2003
    ..We report the case of a 30-year-old woman heterozygous for both the prothrombin 3' UTR mutation and for the factor V Leiden mutation who presented with a proximal deep vein thrombosis following in vitro fertilization...
  79. ncbi Risk factors and recurrence rate of primary deep vein thrombosis of the upper extremities
    Ida Martinelli
    Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Internal Medicine and Dermatology, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Maggiore Policlinico, University of Milano, Italy
    Circulation 110:566-70. 2004
    ..Risk factors for primary upper-extremity DVT are not well established, and the recurrence rate is unknown...
  80. ncbi Haemophilia and thrombophilia: an unexpected association!
    Y Dargaud
    Centre Regional de Traitement des Hemophiles, Hopital Edouard Herriot, Lyon, France
    Haemophilia 10:319-26. 2004
    ....
  81. ncbi Multiple thrombophilic gene mutations rather than specific gene mutations are risk factors for recurrent miscarriage
    Carolyn B Coulam
    Pregnancy Success Center or the Rinehart Center for Reproductive Medicine, Chicago, IL, USA
    Am J Reprod Immunol 55:360-8. 2006
    ..We compared the prevalence of 10 thrombophilic gene mutations among women with a history of recurrent miscarriages and fertile control women...
  82. ncbi High frequency of thrombophilic disorders in women with recurrent fetal miscarriage
    L Onderoglu
    Department of Obstetrics and Gynecology, Hacettepe University School of Medicine, Ankara, Turkey
    Clin Exp Obstet Gynecol 33:50-4. 2006
    ..The rate of Factor V (FV) Leiden mutation, Factor (F) II mutation, protein S, protein C, antithrombin III deficiencies and overall ..
  83. ncbi Double heterozygosity for Factor V Leiden and Factor V Cambridge mutations associated with low levels of activated protein C resistance in a Spanish thrombophilic family
    Amparo Santamaria
    Hemostasis and Thrombosis Unit, Department of Hematology, Hospital de la Santa Creu i Sant Pau, C Sant Antoni Ma Claret, 167, 08025 Barcelona, Spain
    Thromb Haemost 93:1193-5. 2005
  84. ncbi Inherited thrombophilia is associated with deep vein thrombosis in a Colombian population
    J D Torres
    Grupo de Investigacion en Trombosis, Universidad de Antioquia Hospital Universitario San Vicente de Paul, Medellin, Colombia
    Am J Hematol 81:933-7. 2006
    ..6/114 controls (OR = 6.08, 95% CI = 2.23-17.47). Ten of 100 patients carried the factor V Leiden mutation vs. 1/114 controls (OR = 12.56, 95% CI = 1.61-267)...
  85. ncbi Prothrombin A19911G polymorphism and the risk of venous thromboembolism
    I Martinelli
    Department of Internal Medicine and Medical Specialties, A Bianchi Bonomi Haemophilia and Thrombosis Center, University of Milan, and IRCCS Ospedale Maggiore Policlinico, Mangiagalli and Regina Elena Foundation, Milan, Italy
    J Thromb Haemost 4:2582-6. 2006
    ..The A > G polymorphism at position 19911 of the prothrombin gene is associated with increased plasma prothrombin levels but its role as a risk factor for venous thromboembolism (VTE) is not established...
  86. ncbi Evaluation of thrombotic children with malignancy
    Selma Unal
    Section of Pediatric Hematology, Department of Pediatrics, Faculty of Medicine, Hacettepe University, 06100, Ankara, Turkey
    Ann Hematol 84:395-9. 2005
    ..Prothrombotic risk factors such as factor V G1691A and prothrombin G20210A mutation, protein C, protein S, antithrombin III deficiencies, factor VIII and ..
  87. ncbi Issues concerning the laboratory investigation of inherited thrombophilia
    Armando Tripodi
    Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Internal Medicine and Dermatology, University and IRCCS Maggiore Hospital, Milan, Italy
    Mol Diagn 9:181-6. 2005
    ..deficiencies or abnormalities of antithrombin, protein C or protein S; to the presence of a point mutation in the factor V gene (G1691A, factor V Leiden) leading to a poor anticoagulant response to activated protein C; or to the ..
  88. ncbi Thrombophilic gene mutations in cirrhotic patients with portal vein thrombosis
    Ozlem Erkan
    Institute of Hepatology, Ankara University, Ankara, Turkey
    Eur J Gastroenterol Hepatol 17:339-43. 2005
    ..Thrombophilic gene mutations have been reported to be associated with the formation of portal vein thrombosis (PVT). This study aimed to investigate the role of thrombophilic gene mutations in cirrhotic patients with PVT...
  89. ncbi Thrombophilia related issues in women and children
    Ron Hoffman
    Head of Inpatient Hematology Unit, Department of Hematology and Bone Marrow Transplantation, Rambam Medical Center, Bruce Rappaport Faculty of Medicine, Haifa, Israel
    Semin Thromb Hemost 31:97-103. 2005
    ..This article will focuses on the clinical association, pathogenesis, and treatment of thrombophilia-related issues in women and children...
  90. ncbi Learning from peer assessment: the role of the external quality assurance multilaboratory thrombophilia test process
    Emmanuel J Favaloro
    Haemostasis Laboratories, Department of Haematology, Institute of Clinical Pathology and Medical Research ICPMR, Westmead Hospital, Westmead, New South Wales, Australia
    Semin Thromb Hemost 31:85-9. 2005
    ..Testing of some acquired markers of thrombophilia, such as lupus anticoagulant, and genetic tests such as factor V Leiden and prothrombin G20210A mutation, are also available...
  91. ncbi The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies
    Antonio Marchiori
    Department of Emergency Medicine, St Anthony Hospital, University of Padua, Padua, Italy
    Haematologica 92:1107-14. 2007
    b>Factor V Leiden (FVL) and prothrombin G20210A mutation (PTM) are the two most common genetic polymorphisms known to predispose to a first episode of venous thromboembolism (VTE)...
  92. ncbi Multilaboratory testing in thrombophilia through the United Kingdom National External Quality Assessment Scheme (Blood Coagulation) Quality Assurance Program
    Ian Jennings
    United Kingdom NEQAS Blood Coagulation, Sheffield, United Kingdom
    Semin Thromb Hemost 31:66-72. 2005
    ..For protein C (PC) assays 18% of centers reported PC deficiency in a patient homozygous for factor V Leiden...
  93. ncbi [Frequency of antiphospholipid antibodies and factor V (G1691A), prothrombin (G20210A) gene polimorphism among women with pregnancy complications]
    Marcin Rajewski

    Pol Arch Med Wewn 115:417-25. 2006
    ..Diagnostic panel include inherited factors like factor V Leiden and prothrombin mutation, activated protein C resistance and acquired like anticardiolipin antibodies, ..
  94. ncbi Role of thrombophilia in deciding on the duration of anticoagulation
    Kenneth A Bauer
    Veterans Administration Boston Healthcare System and Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02132, USA
    Semin Thromb Hemost 30:633-7. 2004
    ..Discovery of the factor V Leiden and prothrombin G20210A mutations has greatly increased the percentage of patients in whom venous ..
  95. ncbi A review of the clinical and diagnostic utility of laboratory tests for the detection of congenital thrombophilia
    Armando Tripodi
    Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Internal Medicine, University and IRCCS Maggiore Hospital, Milan, Italy
    Semin Thromb Hemost 31:25-32. 2005
    ....
  96. ncbi Primary upper-extremity deep vein thrombosis: high prevalence of thrombophilic defects
    Mariela F Hendler
    Departamento de Hemostasia y Trombosis, Instituto de Investigaciones Hematologicas Mariano R Castex, Academia Nacional de Medicina de Buenos Aires, Buenos Aires, Argentina
    Am J Hematol 76:330-7. 2004
    ..9% anticardiolipin antibodies). Factor V Leiden (12.9%) and prothrombin G20210A mutation (20%) were the most prevalent genetic risk factors...
  97. ncbi Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration
    Celine Straczek
    INSERM, Cardiovascular Epidemiology Unit, Villejuif, France
    Circulation 112:3495-500. 2005
    ..Transdermal estrogen may be safe with respect to VTE. We investigated the impact of the route of estrogen administration on the association between a prothrombotic mutation (factor V Leiden or prothrombin G20210A mutation) and VTE risk.
  98. ncbi Markers of activated coagulation in patients with factor V Leiden and/or G20210A prothrombin gene mutation
    I Gouin-Thibault
    Laboratoire d Hematologie, Hopital Charles Foix, 7 av de la République, 94 205, Ivry sur Seine, France
    Thromb Res 107:7-11. 2002
    The activated protein C (APC) resistance phenotype associated with an abnormal factor V Leiden (FVL), and the G20210A prothrombin gene mutation are the most common findings in patients with venous thromboembolism (VTE)...
  99. ncbi Hereditary thrombophilia in elite athletes
    Thomas Hilberg
    Department of Sports Medicine, Friedrich Schiller University Jena, Jena, Germany
    Med Sci Sports Exerc 34:218-21. 2002
    ..Because high-performance sports are known to carry an increased risk of thrombogenesis, measures to avoid thrombosis must be initiated in cases of known hereditary thrombophilia...
  100. ncbi Primary thrombophilia in Mexico III: A prospective study of the sticky platelet syndrome
    Guillermo J Ruiz-Arguelles
    Centro de Hematologia y Medicina Interna de puebla, Mexico
    Clin Appl Thromb Hemost 8:273-7. 2002
    ..activator inhibitor type 1, IgG and IgM isotypes of anti-phospholipid antibodies, homocysteine levels, the factor V gene Leiden mutation, the 677 C->T mutation in the 5,10-methylen-tetrahydrofolate-reductase (MTHFR), and the ..
  101. ncbi Multiple thrombophilic factors in a patient with Budd-Chiari syndrome
    V Brancaccio
    Coagulation Unit, Cardarelli Hospital, Naples, Italy
    Clin Lab Haematol 24:61-3. 2002
    ..We report the case of a patient with essential thrombocythemia and Budd-Chiari syndrome in which heterozygosity for both factor V Leiden and the mutation G20210A of the prothrombin gene were identified.

Research Grants78

  1. MOLECULAR BIOLOGY OF HUMAN COAGULATION FACTOR V
    Thomas Ortel; Fiscal Year: 2010
    ..A membrane binding site was localized to the factor V C2 domain and the structures of two crystal forms of this domain have been elucidated...
  2. MOLECULAR BIOLOGY OF HUMAN COAGULATION FACTOR V
    WILLIAM KANE; Fiscal Year: 2009
    ..A membrane binding site was localized to the factor V C2 domain and the structures of two crystal forms of this domain have been elucidated...
  3. NICHD Maternal Fetal Medicine Units Network
    Brian Mercer; Fiscal Year: 2007
    ..fetal pulse oximetry in labor, treatment of mild gestational diabetes, vaginal birth after cesarean, Factor V Leiden mutation carriage)...
  4. FACTOR VA INTERACTIONS REGULATING PROTHROMBIN ACTIVATION
    Paul Bock; Fiscal Year: 2007
    b>Factor V plays a pivotal role in hemostasis, and in the pathology of venous thrombosis...
  5. FACTOR VA INTERACTIONS REGULATING PROTHROMBIN ACTIVATION
    Paul E Bock; Fiscal Year: 2010
    b>Factor V plays a pivotal role in hemostasis, and in the pathology of venous thrombosis...
  6. MOLECULAR BIOLOGY OF HUMAN COAGULATION FACTOR V
    WILLIAM KANE; Fiscal Year: 2004
    ..that two tryptophans located in a mobile solvent exposed loop play a critical role in high affinity binding of factor V to phospholipid membranes containing low concentrations of phosphatidylserine...
  7. MOLECULAR BIOLOGY OF HUMAN COAGULATION FACTOR V
    WILLIAM KANE; Fiscal Year: 2007
    ..A membrane binding site was localized to the factor V C2 domain and the structures of two crystal forms of this domain have been elucidated...
  8. MOLECULAR BIOLOGY OF HUMAN COAGULATION FACTOR V
    WILLIAM KANE; Fiscal Year: 1993
    DESCRIPTION: (Adapted from the investigator's abstract). Factor V is a protein cofactor that is essential for the prothrombinase complex. This complex consists of factor Va, factor Xa, calcium, and a phospholipid surface...
  9. Surrogate markers for Severe Pulmonary Embolism
    JEFFREY KLINE; Fiscal Year: 2005
    ..if patients with PE complicated by an adverse outcome are more likely to have antiphospholipid antibodies, or factor V Leiden G1691A, prothrombin G20210A, methylenetetrahydrofolate reductase C677T mutations, or low red blood cell ..
  10. Epidemiologic Study of Placental Abruption
    Cande Ananth; Fiscal Year: 2006
    ..from which DNA will be extracted and assayed for genetic mutations and polymorphisms, including those for factor V Leiden (1691G yields A), prothrombin gene (20210G yields A), the 677C yields T and 1298A yields C polymorphisms ..
  11. Functional Domains of Coagulation Factor V
    Michael Kalafatis; Fiscal Year: 2007
    ..The procofactor, factor V, does not participate in prothrombinase...
  12. Thrombin Formation Inhibitors
    James Phillips; Fiscal Year: 2004
    ..Generation of DVT is strongly correlated with the function of factor V, a protein cofactor for prothrombinase...
  13. MUTATIONS, HORMONE THERAPY, AND VENOUS THROMBOEMBOLISM
    Bruce Psaty; Fiscal Year: 2001
    DESCRIPTION: (Adapted from Investigator's Abstract) Epidemiologic studies have identified Factor V Leiden as the most common cause of heritable thrombophilia a prothrombotic mutation associated with a 5 to 7-fold increase in the risk of ..
  14. PRIMARY STRUCTURE OF PROTHROMBIN
    Kenneth Mann; Fiscal Year: 2003
    b>Factor V is a central participant in the blood clotting process...
  15. Processed Defining Megakaryocyte Endocytosis of Factor V
    PAULA TRACY; Fiscal Year: 2005
    ..the rate of thrombin generation, the physiologic effect being demonstrated by the severe hemorrhage observed in factor V deficiency...
  16. Discovery of antivirals against vaccinia and smallpox
    Robert Ricciardi; Fiscal Year: 2003
    ..The approach may help deliver the 'just-in-time' need for reagents to combat a smallpox bioterrorism threat. ..
  17. COMMON VARIANTS IN CANDIDATE GENES AND PREMATURE MI RISK
    Stephen Schwartz; Fiscal Year: 2001
    ..Those data show that common polymorphisms in genes coding for two clotting factors, coagulation Factor V and coagulation Factor II, are risk factors for MI only among cigarette smokers in this sample...